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QoL improved signiﬁcantly and to a similar degree with both LV and
CV through 1 year, despite differing rates of speciﬁc complications.
Longer term follow-up is needed to assess the durability of QoL
improvement with LV vs. CV in this population.
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BACKGROUND Elevated carbohydrate antigen 125 (CA125) and
N-terminal Pro-Brain Natriuretic Peptide (NTproBNP) have been
associated with adverse outcome after transcatheter aortic valve
implantation (TAVI). The aim of the present study was to perform a
head-to-head comparison of both biomarkers for risk prediction after
TAVI.
METHODS This study includes 363 patients. The primary endpoint
was all-cause death or readmission for worsening congestive heart
failure (CHF) within one year after TAVI and occurred in 16% of the
population. The optimal cut-off in a receiver operating characteristics
(ROC) curve analysis to predict the primary endpoint was 18.4 U/mL
for CA125 and 2570 ng/L for NTproBNP.
RESULTS Elevated CA125 levels were present in 52% and were
associated with a higher rate of the primary endpoint (27% vs. 3%;
p<0.001). In parallel, elevated NTproBNP levels were present in 42%
and were also associated with a higher rate of the primary endpoint
(27% vs. 8%; p<0.001). After multivariable adjustment, elevated
CA125 (hazard ratio (HR) 5.26; 95%CI [2.13-13.00]; p<0.001) and
elevated NTproBNP (HR 2.12; 95%CI [1.12-4.38]; p¼0.022) were
independent predictors of the primary endpoint. To explore the
utility of combining both biomarkers, CA125 was added to the model
containing baseline variables and NTproBNP, with the result that
only CA125 (HR 4.62; 95%CI [1.83-11.65]; p¼0.001), but not
NTproBNP (HR 1.58; 95%CI [0.79-3.13]; p¼0.194) was an independent
predictor of death or readmission for CHF during follow-up. Addition
of CA125 signiﬁcantly improved the predictive capability of the
model (C-statistic: 0.805 vs. 0.776) and the net reclassiﬁcation index
(50%; 95%CI [20-84]) with an integrated discriminative improvement
of 3.0%.CONCLUSION Elevated CA125 and NTproBNP predict adverse clinical
outcome after TAVI. However, when combining both biomarkers the
predictive capacity of CA125 was superior.
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BACKGROUND Low implantation depth has been associated with the
occurrence of new conduction abnormalities after transcatheter
aortic valve implantation. However, the impact of implantation
depth on the mechanical device-host interaction remains unclear.
We used patient-speciﬁc computer simulations to investigate the
pressure that the frame exerts on the surrounding tissues in vicinity
of the atrioventricular (AV) conduction system, at different implan-
tation depths.
METHODS Twenty patients who received an Evolut R (Medtronic,
MN, USA) were included in this study. For each patient, a 3D aortic
model was obtained from pre-operative CT images and a region of
interest in vicinity of the AV conduction system was deﬁned. Finite-
element computer simulations were used to virtually implant the
device at high, medium and low position. From each simulation the
maximum contact pressure exerted by the frame on the region of in-
terest and the relative area of contact were analyzed; differences were
compared with the Friedman test.
RESULTS At high implantation depth (3.31.3 mm) maximum contact
pressure and relative area of contact were 0.28 [0.06-0.38] MPa and 8
[2-13]% respectively, at medium implantation depth (7.21.3 mm)
0.48 [0.35-0.73] MPa and 29 [20-33]%, and at low implantation depth
(10.91.3 mm) 0.62 [0.52-0.69] MPa and 50 [39-55]%. Differences be-
tween the 3 different implantation depths were signiﬁcant (p<0.001)
(Figure 1).
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the tissue in the vicinity of the AV conduction system and the relative
area of contact increase with the depth of valve implantation.
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BACKGROUND Given TAVR’s broadening application, the budget
constraints faced by hospitals, and the higher cost of the TAVR valve
compared to SAVR, there is great interest in understanding how
hospital costs compare between TAVR and SAVR.
METHODS To evaluate in-hospital costs across U.S. hospitals, we
conducted a retrospective analysis of patients undergoing TAVR or
SAVR between January 1, 2014 – September 30, 2016 using the Pre-
mier Hospital Database. Patients were included in the study if they
underwent a TAVR or SAVR procedure based on ICD-9 and -10 pro-
cedure codes and were 65 years or older at the time of the procedure.
Patients were matched 1:1 using propensity score method based on
patient age, Charlson comorbidity index grouping (4 indices),
gender, race, and payor type. In-hospital costs were deﬁned as the
total hospitalization cost including operating room, supply, room
and board, ICU, lab, etc. plus pharmacy cost, adjusted to 2016 dol-
lars. We supplemented this aggregate-level cost analysis by exam-
ining the average in-hospital costs and reimbursement for TAVR and
SAVR at two U.S. hospitals.
RESULTS We matched 13,030 TAVR and SAVR patients in the Premier
Database. The average, unadjusted, total in-patient hospital cost for
TAVR was $60,063 (SD¼$37,962) compared to $60,319 (SD¼$42,144)
for SAVR. The total average supply cost was higher for TAVR by
$11,407 (TAVR¼$26,317, SD: $21,021 versus SAVR¼$14,910, SD:
$10,860). TAVR had lower average differences of $4,857 for room and
board costs (TAVR¼$13,286 versus SAVR¼$18,143); $2,705 for oper-
ating room costs (TAVR¼$9,733 versus SAVR¼$12,438); and $1,450 for
lab costs (TAVR¼$2,520 versus SAVR¼$3,970).
CONCLUSION Average, in-hospital costs between TAVR and SAVR
were comparable, with the lower cost of room and board, operating
room, and lab offsetting the higher supply cost for TAVR.
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BACKGROUND TAVR is associated with a spectrum of brain injuries.
Studies have correlated the likelihood of neurological events with
increasing magnitude of microemboli. Recently, a Cerebral Protection
System became FDA approved to reduce the risk of stroke during
TAVR. Our study evaluated the generation of microemboli during the
stages of TAVR.
METHODS Single center, TAVR database queried 1/2013-12/2014, to
identify patients who had neuromonitoring during TAVR. 62 patients
had complete bilateral data. Neuromonitoring measured cerebral
microembolic HITS and bilateral oxygen saturation. Data points were
recorded cumulatively: pre-incision, pre-valvuloplasty, valvuloplasty,
valve replacement (deﬁned as the valve crossing the annulus), end of
1st pacing run, post-deployment, and closing. The increase between
two successive time points was calculated by percent increase.
RESULTS Figure 1 shows the pattern of HITS. 24 (38%) patients had
pre-valvuloplasty HITS measured at 0. Pre-valvuloplasty to valvulo-
plasty median increase in HITS was 81% left, 112% right side. Valvu-
loplasty to crossing the annulus, median increase 63% bilaterally.
From crossing to the end of 1st pacing, HITS increase 106% left and
97% right. From 1st pacing run to post-deployment, bilateral increase
33%. Post-deployment to closing increase was 11% left, 6% right.
CONCLUSION The maximum increase in the microemboli during
TAVR occurred between the valve crossing the annulus and the end of
the 1st pacing run. Studies using the embolic protection devices are
warranted to identify the efﬁcacy in reducing microemboli at the time
of valve deployment.
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BACKGROUND The use of embolic protection devices (EPD) may
theoretically reduce the occurrence of cerebral embolic lesions during
transcatheter aortic valve implantation (TAVI). Available evidences
from single studies are quite inconclusive. The aim of the presentmeta-
analysis was to assess the safety and efﬁcacy proﬁle of current EPD.
METHODS EMBASE, PubMed, Web of Science Core Collection, and the
Cochrane Library were searched up to May 2017 for studies that
evaluated patients undergoing TAVI with or without EPD. Endpoint of
